The overall positive rate of RASSF1A was 52%, and the detection sensitivities of the percutaneous biopsy preservation fluid for adenocarcinoma, squamous cell carcinoma, small cell lung cancer, and unclassified lung cancer were 57.1%, 27.8%, 100%, and 39.1% respectively. This evidence concerns the gene RASSF1 and adenocarcinoma.